Konishi M, Kikuchi-Yanoshita R, Tanaka K, Sato C, Tsuruta K, Maeda Y, Koike M, Tanaka S, Nakamura Y, Hattori N
Department of Biochemistry, Tokyo Metropolitan Institute of Medical Science.
Jpn J Cancer Res. 1993 Aug;84(8):893-9. doi: 10.1111/j.1349-7006.1993.tb02063.x.
Loss of heterozygosity (LOH) on chromosomes 1p, 4q, 5q, 8p, 13q, 16q, 17p, and 22q, and mutation of the p53 gene were simultaneously analyzed in 63 hepatocellular carcinomas (HCCs) with distinct histopathological grades, 80% of the tumors being from patients who had been exposed to hepatitis B virus (HBV) or hepatitis C virus (HCV). The frequencies of LOH on 8 chromosomes were 0-25% in 10 well differentiated HCCs, LOH being observed on 4q, 5q and 17p, 21-53% in 26 moderately differentiated HCCs, LOH on 8p and 17p being high, and 29-75% in 27 poorly differentiated HCCs, LOH on 17p, 4q and 8p being the most frequent. p53 gene mutation was detected in moderately and poorly differentiated HCCs at 15% and 52%, respectively, but not at all in well differentiated HCCs. Of the mutations detected, 42% were transition mutation and only 5% were CpG transition, in contrast to the high frequencies of these types of mutations in colon tumors (78% and 54%, respectively). LOH on every chromosome and p53 mutation were more frequent in more advanced tumors, and accumulation of genetic changes increased with increase of the histopathological grade. Frequency of genetic changes in HCCs from HBV-positive patients was comparable to that from HCV-positive patients. The present results suggest that accumulation of genetic changes in multiple tumor suppressor genes, especially LOH on 17p, 4q and 8p, and mutation in p53 gene, are involved in the progression of liver cancer, and LOH on 17p and 4q precedes other genetic changes. Differences in the direction of p53 mutation between HCC and colon carcinoma suggest that liver carcinogens are distinct from colon carcinogens. Furthermore, mechanisms affecting the frequency of LOH in HCCs in HBV-infected patients may be similar to those in HCV-infected patients.
在63例具有不同组织病理学分级的肝细胞癌(HCC)中,同时分析了1p、4q、5q、8p、13q、16q、17p和22q染色体上的杂合性缺失(LOH)以及p53基因的突变情况,其中80%的肿瘤来自感染乙型肝炎病毒(HBV)或丙型肝炎病毒(HCV)的患者。在10例高分化HCC中,8条染色体上的LOH频率为0 - 25%,在4q、5q和17p上观察到LOH;在26例中分化HCC中,LOH频率为21 - 53%,8p和17p上的LOH较高;在27例低分化HCC中,LOH频率为29 - 75%,17p、4q和8p上的LOH最为常见。在中分化和低分化HCC中检测到p53基因突变的比例分别为15%和52%,而在高分化HCC中未检测到。在检测到的突变中,42%为转换突变,只有5%为CpG转换,这与结肠癌中这些类型突变的高频率(分别为78%和54%)形成对比。在更晚期的肿瘤中,每条染色体上的LOH和p53突变更为频繁,并且随着组织病理学分级的增加,基因变化的积累也增加。HBV阳性患者的HCC中基因变化的频率与HCV阳性患者的相当。目前的结果表明,多个肿瘤抑制基因的基因变化积累,尤其是17p、4q和8p上的LOH以及p53基因的突变,参与了肝癌的进展,并且17p和4q上的LOH先于其他基因变化。HCC和结肠癌之间p53突变方向的差异表明,肝癌致癌物与结肠癌致癌物不同。此外,影响HBV感染患者HCC中LOH频率的机制可能与HCV感染患者的相似。